Drummer died of overdose on prescription medicine drugs
NEW YORK -- Steve Foley, wHO played drums with the Replacements at the shadow end of their life history, died utmost weekend in Minneapolis. He was 49. According to local media reports, Foley died afterward accidentally overdosing on prescription medication.
The 1990 selection of Foley, wHO played in such Minneapolis bands as Curtiss A, Wheelo and Snaps, as the fill-in for original Replacements drummer Chris Mars has become the stuff of legend.
According to Jim Walsh's oral history "All Over But the Shouting," frontman Paul Westerberg and bassist Tommy Stinson bumped into Foley at a local bar and procured a sit from him to an audition. In the elevator car was a copy of the mark new Replacements album "All Shook Down," prompting Westerberg and Stinson to see at each other and then exclaim to Foley, "You're already in."
Foley then toured with the band until its final usher on July 4, 1991, in Chicago's Grant Park. Afterward, he and his brother Kevin joined Stinson's band Bash & Pop. Of late, he was working as a car salesman in Minneapolis.
According to the Minneapolis Star Tribune, visitation will be held 11 a.m. Friday at Washburn-McReavy Funeral Chapel in Edina, Minn., with burial to follow at Lakewood Cemetery.
Sunday, 31 August 2008
Thursday, 21 August 2008
Download Hatfield And The North mp3
 Artist: Hatfield And The North: mp3 download Genre(s): Rock Discography:  Hatfield And The North Year: 1973 Tracks: 17 Emerging from the Canterbury, England melodious community which also launched Gong and Kevin Ayers' the Whole World, the capricious progressive stone unit Hatfield and the North formed in 1972. Named in pureness of a throughway world house outside of London, the group's initiation rank brought together a who's-who of the Canterbury artistic production rock word-painting -- vocalist/bassist Richard Sinclair was a early extremity of Caravan, guitar player Phil Miller had tenured with Robert Wyatt in Matching Mole, and drummer Pip Pyle had served with both Gong and Delivery. After a series of line up shuffles, keyboardist Dave Stewart (an alumnus of Egg) was brought in to smash the wheel, and in tandem with the Northettes -- a triple of championship vocalists consisting of Barbara Gaskin, Amanda Parsons and Ann Rosenthal -- the mathematical group began gigging regularly. Upon signing to Virgin, Hatfield and the North recorded their 1974 self-titled debut LP, a flashy, for the most part improvisational work middle 'tween melodic pop and more van stylings. A individual, "Let's Eat (Real Soon)," appeared at the end of the year, and in 1975 the mathematical group resurfaced with The Rotters Club; although the record briefly landed in the U.K. charts, their commercial future looked dim, and so Hatfield and the North disbanded inside months of the album's going. Sinclair soon coupled Camel, while Stewart recorded with Bill Bruford earlier finding pop success in 1981 with ex-Zombie Colin Blunstone on a compensate of the Jimmy Ruffin chestnut "What Becomes of the Broken Hearted?" In 1989, Hatfield and the North reunited, minus Stewart, for a series of live dates; a document of the performances, Live 1990, followed in 1993. |
Monday, 11 August 2008
"Chick flicks" face uphill battle in Hollywood
LOS ANGELES () - When "Sex and the City" debuted at No. 1 at box offices earlier this year, headlines trumpeted the unusual success of a film nigh women aimed at women, and industry watchers forecast more of the same ahead.
But female writers, directors and producers say the blockbuster is an exclusion to the general Hollywood rule that films about women get second-class treatment compared with big-budget action flicks like the Batman movie "The Dark Knight," which is aimed at young hands.
These women see business-as-usual for Hollywood, and that means fewer movies focused on women's lives.
Underlying the dilemma for women is that box office prospects for their movies are, generally speaking, seen as less lucrative than for adventures such as "Dark Knight." As a result, the major studios make fewer of them and they get less money for production and marketing.
"Women much are interested in news report, true emotions and rounded characters," aforesaid Diane English, director of "The Women," set for a September debut. "And often we find action flicks less interesting because they deficiency those elements."
This week, "The Sisterhood of the Traveling Pants 2" opened in U.S. theaters as the latest case of a girl-oriented celluloid that hopes to become a break hit at box offices. It tells of the friendship of four college-age women.
But dissimilar "Sex," which opened in late May and grossed nearly $375 million world-wide, "Traveling Pants" does non benefit from a inbuilt audience of a major television hit like HBO comedy "Sex and the City," and Hollywood's studios like to base movies on products with proven audiences.
WANTED: WOMEN STUDIO EXECS�
More info
Wednesday, 6 August 2008
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application To FDA For Rivaroxaban
�Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for rivaroxaban, an investigational, oral, once-daily anticoagulant for the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery.
In 2005, J&JPRD entered into an agreement with Bayer HealthCare AG to jointly develop rivaroxaban. If sanctioned by the FDA, Ortho-McNeil, a Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., will market the drug in the U.S. Bayer HealthCare holds marketing rights in countries outside the U.S.
Venous blood clots, also known as venous thromboembolism (VTE), include DVT - a blood clog in a large vein, usually in the legs - and PE - a blood clot that has travelled to the lungs - both of which are life-threatening just often preventable complications following major orthopedical surgery. Annually in the U.S., more than 900,000 mass suffer from VTE events, and three hundred,000 individuals die from VTE. Patients undergoing hip or knee joint replacement surgery are at high danger for VTE because the large veins of the leg that carry blood back to the heart are significantly damaged during these procedures. In fact, venous rip clots occur in up to 40% of patients undergoing major orthopedic operating room who do not receive preventative charge. Each year, approximately 700,000 Americans elect to have rosehip and knee replacement surgeries, and a blood clabber is the most common cause of re-hospitalization for this patient group.
The filing was supported by data from the world-wide RECORD (REgulation of Coagulation in major Orthopedic oR reducing the Risk of DVT and PE) clinical trial program. The RECORD program involved more than 12,500 patients in four studies and compared rivaroxaban to injected enoxaparin, for the prevention of total VTE in patients undergoing either total knee or hip replacement surgery.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) is a wholly-owned subsidiary of Johnson & Johnson, the world's most broadly based producer of health attention products. J&JPRD is headquartered in Raritan, N.J., and has facilities throughout Europe, the United States and Asia. J&JPRD is leveraging drug breakthrough and do drugs development in a variety show of therapeutical areas, including CNS, Internal Medicine and Oncology, to address unmet medical of necessity worldwide. More information tin can be institute at hTTP://www.jnjpharmarnd.com.
This press tone ending contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on stream expectations of future events. If underlying assumptions show inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as stake rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new production development, including obtaining regulative approvals; domestic and alien health maintenance reforms and governmental pentateuch and regulations; and trends toward health care price containment. A further list and description of these risks, uncertainties and other factors posterior be institute in Exhibit 99 of Johnson & Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are usable online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
More information
In 2005, J&JPRD entered into an agreement with Bayer HealthCare AG to jointly develop rivaroxaban. If sanctioned by the FDA, Ortho-McNeil, a Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., will market the drug in the U.S. Bayer HealthCare holds marketing rights in countries outside the U.S.
Venous blood clots, also known as venous thromboembolism (VTE), include DVT - a blood clog in a large vein, usually in the legs - and PE - a blood clot that has travelled to the lungs - both of which are life-threatening just often preventable complications following major orthopedical surgery. Annually in the U.S., more than 900,000 mass suffer from VTE events, and three hundred,000 individuals die from VTE. Patients undergoing hip or knee joint replacement surgery are at high danger for VTE because the large veins of the leg that carry blood back to the heart are significantly damaged during these procedures. In fact, venous rip clots occur in up to 40% of patients undergoing major orthopedic operating room who do not receive preventative charge. Each year, approximately 700,000 Americans elect to have rosehip and knee replacement surgeries, and a blood clabber is the most common cause of re-hospitalization for this patient group.
The filing was supported by data from the world-wide RECORD (REgulation of Coagulation in major Orthopedic oR reducing the Risk of DVT and PE) clinical trial program. The RECORD program involved more than 12,500 patients in four studies and compared rivaroxaban to injected enoxaparin, for the prevention of total VTE in patients undergoing either total knee or hip replacement surgery.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) is a wholly-owned subsidiary of Johnson & Johnson, the world's most broadly based producer of health attention products. J&JPRD is headquartered in Raritan, N.J., and has facilities throughout Europe, the United States and Asia. J&JPRD is leveraging drug breakthrough and do drugs development in a variety show of therapeutical areas, including CNS, Internal Medicine and Oncology, to address unmet medical of necessity worldwide. More information tin can be institute at hTTP://www.jnjpharmarnd.com.
This press tone ending contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on stream expectations of future events. If underlying assumptions show inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as stake rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new production development, including obtaining regulative approvals; domestic and alien health maintenance reforms and governmental pentateuch and regulations; and trends toward health care price containment. A further list and description of these risks, uncertainties and other factors posterior be institute in Exhibit 99 of Johnson & Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are usable online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
More information
Subscribe to:
Posts (Atom)